Are biological agents toxic to human chondrocytes and osteocytes?

Journal of Orthopaedic Surgery and Research

Mahir Mahirogullari⁶  Aliye Yildirim Guzelant²  Duygu Yasar Sirin⁴  Selami Cakmak⁵  Ibrahim Yilmaz¹  Bulent Bilir³  Mehmet Isyar⁶ 

[1] Department of Pharmacovigilance and Rational Drug Use Team, Republic of Turkey, Ministry of Health, State Hospital, Tekirdag, 59100, Turkey;Department of Physical Medicine and Rehabilitation, School of Medicine, Namik Kemal University, Tekirdag, 59100, Turkey;Department of Internal Medicine, School of Medicine, Namik Kemal University, Tekirdag, 59100, Turkey;Faculty of Science, Department of Molecular Biology and Genetics, Namik Kemal University, Tekirdag, 59100, Turkey;Department of Orthopaedic and Traumatology, Haydarpasa Training Hospital, Gulhane Military Medical Academy, 34668, Istanbul, Turkey;Department of Orthopaedic and Traumatology, School of Medicine, Istanbul Medipol University, Bagcilar, Istanbul, 34214, Turkey

关键词: Primary cell culture;    Osteotoxicity;    Chondrotoxicity;    Biological agents;   

Others  :  1226930
DOI  :  10.1186/s13018-015-0264-y

 received in 2015-04-07, accepted in 2015-07-16,  发布年份 2015

【 摘 要 】

Purpose

The aim of the present study is to investigate the effects of biological agents (BAs) on human chondrocytes and osteocytes in vitro.

Methods

Primary cell cultures obtained from gonarthrosis patients were divided into four groups, two of which were designated as control cultures of chondrocyte and osteocyte, and the other two groups were exposed to BAs administered via the culture medium. Cultured cells were characterized by immunophenotyping. Before and after administration of the agents, the cultures were observed by inverted and environmental scanning electron microscopy (ESEM). The number of live cells and the proliferation rate were monitored by MTT assay.

Results

Rituximab and adalimumab were the least toxic agents to chondrocytes, whereas adalimumab and etanercept were to osteocytes.

Conclusion

During periods of intense active inflammation, the concentration of the preferred BAs after inhibition of inflammation needs to be emphasized when their effects on cartilage and bone tissue are considered at the cellular level if the clinical practice is to continue.

【 授权许可】

   
2015 Isyar et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

【 参考文献 】

• [1]Sen D, Paul JR, Ranganathan P. Pharmacogenetics in rheumatoid arthritis. Methods Mol Biol. 2014; 1175:625-660.
• [2]Li Y, Wang Y, Shi G. Progress of biological agents on psoriatic arthritis. Curr Pharm Biotechnol. 2014; 15:525-534.
• [3]Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K et al.. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011; 15(14):1-278.
• [4]Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T et al.. Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity. Clin Rheumatol. 2014; 33(1):39-47.
• [5]Hasler P. Biological therapies directed against cells in autoimmune disease. Springer Semin Immunopathol. 2006; 27(4):443-56.
• [6]Scher JU. Monotherapy in rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71(3):204-7.
• [7]Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009; 36(6):1118-25.
• [8]Movva R, Brown SB, Morris DL, Figueredo VM. Anakinra for myocarditis in juvenile idiopathic arthritis. Tex Heart Inst J. 2013; 40:623-625.
• [9]Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC et al.. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis. 2014; 73:909-912.
• [10]Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006; 33:2398-2408.
• [11]Malik D, Tarek M, Caceres del Carpio J, Ramirez C, Boyer D, Kenney MC et al.. Safety profiles of anti-VEGF drugs: bevacizumab ranibizumab aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014; 98:11-16.
• [12]Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthritis. Ann Rheum Dis. 1957; 16:494-502.
• [13]Yilmaz I, Gokay NS, Gokce A, Tonbul M, Gokce C. A novel designed chitosan based hydrogel which is capable of consecutively controlled release of TGF-beta 1 and BMP-7. Turkiye Klinikleri Journal of Medical Sciences. 2013; 33:18-32.
• [14]Gokce A, Yilmaz I, Gokay NS, Can L, Gokce C. Does insulin transferrin and selenous acid preparation effect chondrocyte proliferation? Acta Orthop Traumatol Turc. 2014; 48:313-319.
• [15]Yilmaz I, Gokay NS, Gokce A. In-vitro differentiation: from a primary cell to the osteoblast. Turkiye Klinikleri J Orthop & Traumatol-Special Topics. 2013; 6:7-15.
• [16]Zheng L, Jiang X, Chen X, Fan H, Zhang X. Evaluation of novel in situ synthesized nano-hydroxyapatite/collagen/alginate hydrogels for osteochondral tissue engineering. Biomed Mater. 2014; 9:065004.
• [17]Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med (Maywood). 2001; 226:507-520.
• [18]Gallego-Galisteo M, Villa-Rubio A, Alegre-del Rey E, Márquez-Fernández E, Ramos-Báez JJ. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2012; 2012(37):301-307.
• [19]Beyzadeoglu T, Torun KG, Ekinci ID, Bekler H, Yilmaz C. Cytotoxicity of local anesthetics to rats’ articular cartilage: an experimental study. Acta Orthop Traumatol Turc. 2012; 46:201-207.
• [20]Marmotti A, de Girolamo L, Bonasia DE, Bruzzone M, Mattia S, Rossi R et al.. Bone marrow derived stem cells in joint and bone diseases: a concise review. Int Orthop. 2014; 38:1787-1801.
• [21]Gokce A, Yilmaz I, Bircan R, Tonbul M, Gokay NS, Gokce C. Synergistic effect of TGF-β1 and BMP-7 on chondrogenesis and extracellular matrix synthesis: an in vitro study. Open Orthop J. 2012; 6:406-413.
• [22]Murdaca G, Spanò F, Contatore M, Guastalla A, Magnani O, Puppo F. Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy. Expert Opin Drug Metab Toxicol. 2014; 10:1-8.
• [23]Goodwin W, McCabe D, Sauter E, Reese E, Walter M, Buckwalter JA et al.. Rotenone prevents impact-induced chondrocyte death. J Orthop Res. 2010; 8:1057-1063.
• [24]Stamp LK, Barclay M. Therapeutic drug monitoring in rheumatic diseases: utile or futile? Rheumatology (Oxford). 2014; 53:988-997.
• [25]Elsner A, Lange F, Fitzner B, Heuschkel M, Krause BJ, Jaster R. Distinct antifibrogenic effects of erlotinib sunitinib and sorafenib on rat pancreatic stellate cells. World J Gastroenterol. 2014; 28:7914-7925.
• [26]Dragoo JL, Korotkova T, Kim HJ, Jagadish A. Chondrotoxicity of low pH epinephrine and preservatives found in local anesthetics containing epinephrine. Am J Sports Med. 2010; 38:1154-1159.
• [27]Anz A, Smith MJ, Stoker A, Linville C, Markway H, Branson K et al.. The effect of bupivacaine and morphine in a coculture model of diarthrodial joints. Arthroscopy. 2009; 25:225-231.
• [28]Hao J, Varshney RR, Wang DA. Engineering osteogenesis and chondrogenesis with gene-enhanced therapeutic cells. Curr Opin Mol Ther. 2009; 11:404-410.
• [29]Syed HM, Green L, Bianski B. Bupivacaine and triamcinolone may be toxic to human chondrocytes: a pilot study. Clin Orthop Relat Res. 2011; 469:2941-2947.
• [30]Holford NHG. Drug receptors and pharmacodynamics. In: Basic and clinical pharmacology. Katzung B, Trevor A, editors. McGrraw-Hill Companies Inc., Lange Medical Publications, California; 2015: p.20-41.
• [31]Correia MA. Drug biotransformation. In: Basic and clinical pharmacology. Katzung B, Trevor A, editors. McGrraw-Hill Companies Inc., Lange Medical Publications, California; 2015: p.56-74.
• [32]Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A et al.. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008; 58:1248-1257.
• [33]Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeers P et al.. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005; 21:251-258.
• [34]Hu Y, Tang XX, He HY. Gene expression during induced differentiation of sheep bone marrow mesenchymal stem cells into osteoblasts. Genet Mol Res. 2003; 12:6527-6534.